Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-12-11
2008-11-18
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266400, C514S266220, C514S367000, C514S375000, C544S291000, C544S293000, C548S161000, C548S222000, C548S308700
Reexamination Certificate
active
07452912
ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knuppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 2259224 (1978-01-01), None
patent: 2241149 (1999-10-01), None
patent: 2655636 (1977-06-01), None
patent: 19548709 (1977-07-01), None
patent: 19654483 (1998-01-01), None
patent: 19713000 (1998-10-01), None
patent: 0147211 (1985-07-01), None
patent: 0288176 (1988-10-01), None
patent: 0330506 (1989-08-01), None
patent: 0330506 (1989-08-01), None
patent: 0526348 (1993-02-01), None
patent: 0535521 (1993-04-01), None
patent: 92/16549 (1992-10-01), None
patent: 93/12809 (1993-07-01), None
patent: 96/01644 (1996-01-01), None
patent: 96/22966 (1996-08-01), None
patent: 98/33783 (1998-08-01), None
patent: 98/53817 (1998-12-01), None
patent: 99/06390 (1999-02-01), None
patent: 99/06391 (1999-02-01), None
patent: 99/06431 (1999-02-01), None
patent: 99/06432 (1999-02-01), None
patent: 99/06433 (1999-02-01), None
patent: 99/10312 (1999-03-01), None
patent: 99/10313 (1999-03-01), None
patent: 99/37618 (1999-07-01), None
patent: 99/52898 (1999-10-01), None
Gonzalez-Amaro et al., Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords?, Immunology, vol. 116, No. 3, pp. 289-296, Nov. 2005.
Abraham, et al.J. Clin. Invest.93:776 (1994).
Advani S.B. , et al.J Pharm. Sci.57:10:1693-1696 (1968).
Bao, et al.Diff., 52:239 (1993).
Baron, et al.J. Exp. Med.177:57 (1993).
Baron, et al.J. Clin. Invest.93:1700 (1994).
Burkly, et al.Diabetes. 43:529 (1994).
Cybulsky, et al.Science. 251:788 (1991).
Elices, et al.J. Clin. Invest.93:405 (1994).
Elices, et al.Cell.60:577-584 (1990).
Gordeev M.F.Biotech. and Bioeng.61(1):13-16 (1998).
Hamann, et al.J. Immunology.152:3283 (1994).
Henke et al.J. Med. Chem.41:5020-5036 (1998).
Hladon, B., et al.“In Vitro cytostatic activity of some amino acid 4-N-substituted cytosines.”Arch. Immunol. Ther. Exp.40(2):145-50 (1992) (Abstract).
Hoffman, S., et al. “N-Pyrimidinylamino acids. III. N-(oxopyrimidinyl) derivatives of neutral amino acids.”Z. Chem.12(1):21-2 (1972) Coden: Zeceal (Abstract).
Kawaguchi, et al.Japanese J. Cancer Res.83:1304 (1992).
Lauri, et al.British J. Cancer. 68:862 (1993).
Lazar et al.J Med Chem. 37:913-923 (1994).
Ma, et al.J. Am. Chem. Soc.120:12459-12467 (1998).
Li, et al.Arterioscler. Thromb.13:197 (1993).
Mulligan, et al.J. Immunology. 150:2407 (1993).
Okarhara, et al.Can. Res.54:3233 (1994).
Osborn.Cell. 62:3-6 (1990).
Paavonen, et al.Int. J. Can. 58:298 (1994).
Paul, et al.Transpl. Proceed.25:813 (1993).
Postigo, et al.J. Clin. Invest. 89:1445 (1991).
Pretolani, et al.J. Exp. Med.180:795 (1994).
Sasseville, et al.Am. J. Path.144:27 (1994).
Schadendorf, et al.J. Path.170:429 (1993).
Springer.Nature. 346:425-434 (1990) .
Teranishi, K., et al. “Synthesis and Chemiluminescense of Coelenterazine (Oplophorus Luciferin) analogs.”Bull. Chem. Soc. Jpn.. 63(11):3132-40 (1990) (Abstract).
Van Dinther-Janssen, et al.Annals. Rheumatic Dis.52:672 (1993).
Van Dinther-Janssen, et al.J. Immunology. 147:4207 (1991).
Vedder, et al.Surgery. 106:509 (1989).
Yang, et al.Proc. Nat. Acad. Science(USA). 90:10494 (1993).
Yednock, et al.Nature. 356:63 (1992).
Grant Francine S.
Konradi Andrei W.
Pleiss Michael A.
Thorsett Eugene D.
Coleman Brenda L
Elan Pharmaceuticals Inc.
Foley & Lardner LLP
Wyeth
LandOfFree
Fused ring heteroaryl and heterocyclic compounds which... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused ring heteroaryl and heterocyclic compounds which..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused ring heteroaryl and heterocyclic compounds which... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4035502